A steady throughput of new agents for the treatment of myeloma - 100038

Spotlight
Video

A steady throughput of new agents for the treatment of myeloma

patientpower has 2417 videos Subscribe Here

Loading........
Description: At the 20th Congress of the European Hematology Association (EHA), Prof Paul Richardson, of the Dana-Farber Cancer Institute, Boston, MA, talks about the plethora of promising new agents, including proteasome inhibitors, monoclonal antibodies, histone deacetylase (HDAC) inhibitors, that are in clinical development for the treatment of patients with myeloma.
Shared By : patientpower
Posted on : 07/03/15
Added : 3 years ago
Category : Multiple Myeloma



Recommended

Nothing found.